IPX159

Impax Laboratories, LLC · Phase 2 active Small molecule

At a glance

Generic name	IPX159
Sponsor	Impax Laboratories, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IPX159 CI brief — competitive landscape report
IPX159 updates RSS · CI watch RSS
Impax Laboratories, LLC portfolio CI